Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity (2020 - 2025)

Apellis Pharmaceuticals has reported Common Equity over the past 6 years, most recently at $370.1 million for Q4 2025.

  • Quarterly results put Common Equity at $370.1 million for Q4 2025, up 61.96% from a year ago — trailing twelve months through Dec 2025 was $370.1 million (up 61.96% YoY), and the annual figure for FY2025 was $370.1 million, up 61.96%.
  • Common Equity for Q4 2025 was $370.1 million at Apellis Pharmaceuticals, down from $401.2 million in the prior quarter.
  • Over the last five years, Common Equity for APLS hit a ceiling of $462.2 million in Q1 2022 and a floor of -$141.5 million in Q2 2021.
  • Median Common Equity over the past 5 years was $234.7 million (2023), compared with a mean of $229.9 million.
  • Biggest five-year swings in Common Equity: crashed 160.97% in 2021 and later skyrocketed 794.8% in 2022.
  • Apellis Pharmaceuticals' Common Equity stood at $198.7 million in 2021, then decreased by 14.49% to $169.9 million in 2022, then grew by 14.51% to $194.5 million in 2023, then rose by 17.49% to $228.5 million in 2024, then surged by 61.96% to $370.1 million in 2025.
  • The last three reported values for Common Equity were $370.1 million (Q4 2025), $401.2 million (Q3 2025), and $156.3 million (Q2 2025) per Business Quant data.